Prostate cancer is a major public health problem, having caused more than 375,000 deaths worldwide in 2020. 1 One of the main tools available to lessen this burden is prostate-specific antigen (PSA) screening. Large, randomized trials have shown that PSA screening significantly reduces the risk of death from prostate cancer. 2 However, PSA screening also incurs substantial harms, most importantly overdiagnosis — the diagnosis of disease that would not have been diagnosed without screening — and the complications of associated treatment. 3 One approach to realizing the benefit of PSA screening while curtailing overdiagnosis is to administer a triage test in patients with . . .